Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6982349 | 0.83 | POLB (0.46) | SMN1; SMN2TDP1MAPK1LMNAMEN1 | |
| SCHEMBL6986386 | 0.82 | CHRNB2 (0.46) | SMN1; SMN2TDP1MAPK1LMNAMEN1 | |
| SCHEMBL6981391 | 0.81 | MAPT (0.43) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6985757 | 0.81 | MAPT (0.43) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6984495 | 0.79 | DDB1 (0.45) | LMNAMEN1KMT2A | |
| SCHEMBL6247618 | 0.74 | BRD4 (0.50) | BRD4SMN1; SMN2CFTRGOPCLDHA | |
| SCHEMBL157619 | 0.74 | BRD4 (0.50) | BRD4SMN1; SMN2CFTRGOPCLDHA | |
| SCHEMBL9295153 | 0.74 | BRD4 (0.50) | BRD4SMN1; SMN2CFTRGOPCLDHA | |
| SCHEMBL6978724 | 0.73 | MAPT (0.48) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL24625215 | 0.68 | CFTR (0.59) | SMN1; SMN2TDP1CFTRGOPCMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1050530-B1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | SERVIER LAB (FR) | 2003-10-22 | — | — | EP | claimed |
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | RAULT SYLVAIN (FR) | 2002-04-11 | — | — | US | claimed |
| US-6323222-B1 | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | claimed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | claimed |
| CN-114409590-A | Compound with dihydropyridinitrile structure and preparation method and application thereof | 河南新中飞照明电子有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-1050530-B1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | SERVIER LAB (FR) | 2003-10-22 | — | — | EP | disclosed |
| US-6451789-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | LES LABORTOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | RAULT SYLVAIN (FR) | 2002-04-11 | — | — | US | disclosed |
| US-6323222-B1 | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| JP-2000351766-A | NEW 1-AZA-2-ALKYL-6-ARYL-CYCLOALKANE COMPOUND, ITS PRODUCTION AND MEDICINAL COMPOSITION CONTAINING THE SAME | ADIR | 2000-12-19 | — | — | JP | disclosed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | disclosed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | SULT2A1, GRIN2A, NR3C1 | BRD4 2576/4885SMN1; SMN2 682/4885TDP1 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.